What is the difference between Angiotensin (1-7) and ARA-290?

Angiotensin (1-7): Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Is Angiotensin (1-7) FDA approved?

Angiotensin (1-7) is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is Angiotensin (1-7) administered in research settings?

In research settings, Angiotensin (1-7) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Angiotensin (1-7) vs ARA-290

Peptide Comparison

Angiotensin (1-7) vs ARA-290

Name: Angiotensin (1-7) vs ARA-290 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

17 providers listed

Full ARA-290 profile →

Bottom line

Angiotensin (1-7) carries stronger published evidence (RCT, 9 key studies) than ARA-290 (RCT, 2); both are research compounds.

Quick Verdict

Angiotensin (1-7)

Half-life

~9–10 sec (rat)

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Angiotensin (1-7)
Less frequent dosing (longer half-life)	Angiotensin (1-7)
More provider options (0 vs 17)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Angiotensin (1-7)

ARA-290

Mechanism Family

Longevity & Cellular

Half-life

~9–10 sec (rat)

~2 min (IV); ~10–20 min (SC)

FDA Status

investigational

Admin Routes

subcutaneous, intravenous

Availability

Research Only

Providers

None listed

17 listed

Avail. Notes

—

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Research Evidence

Angiotensin (1-7)

RCT · 9 key studies · most recent 2026

ARA-290

RCT · 2 key studies · most recent 2026

Research Citations

Angiotensin (1-7)

RCT2026 · J Alzheimers Dis

Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.

RCT2024 · Annals of Intensive Care

Angiotensin-(1-7) improves oxygenation in mechanically ventilated COVID-19 patients: a randomized phase 1-2 s…

Case series2026 · Res Sq

Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…

Animal2026 · Metabolites

The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.

+5 more

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas

cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Price (per mg)

Angiotensin (1-7)

Not enough vendor pricing yet.

ARA-290

$4.95/mg

$3.91 – $5.56 range

34 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Angiotensin (1-7)

Browse directory →

Providers offering

ARA-290

17 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Angiotensin (1-7) vs ARA-290 — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/angiotensin-1-7/ara-290

https://peptidebase.io/peptides/compare/angiotensin-1-7/ara-290 Methodology License Download JSON Download CSV